Disc Medicine (IRON) Stock Forecast, Price Target & Predictions
IRON Stock Forecast
Disc Medicine stock forecast is as follows: an average price target of $66.86 (represents a 41.86% upside from IRON’s last price of $47.13) and a rating consensus of 'Buy', based on 13 wall street analysts offering a 1-year stock forecast.
IRON Price Target
IRON Analyst Ratings
Disc Medicine Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Oct 23, 2024 | Roger Song | Jefferies | $89.00 | $50.92 | 74.78% | 88.84% |
Sep 16, 2024 | Douglas Tsao | H.C. Wainwright | $70.00 | $47.79 | 46.47% | 48.53% |
Aug 22, 2024 | Tiago Fauth | Wells Fargo | $75.00 | $49.31 | 52.10% | 59.13% |
Aug 08, 2024 | Danielle Brill | Raymond James | $50.00 | $42.85 | 16.69% | 6.09% |
Jun 17, 2024 | Evan David Seigerman | BMO Capital | $70.00 | $45.80 | 52.84% | 48.53% |
May 10, 2024 | Danielle Brill | Raymond James | $43.00 | $29.95 | 43.57% | -8.76% |
Apr 02, 2024 | Evan David Seigerman | BMO Capital | $50.00 | $34.21 | 46.16% | 6.09% |
Apr 01, 2024 | Ben Burnett | Stifel Nicolaus | $71.00 | $34.21 | 107.54% | 50.65% |
Apr 01, 2024 | David Nierengarten | Wedbush | $43.00 | $32.00 | 34.38% | -8.76% |
Apr 01, 2024 | Danielle Brill | Raymond James | $40.00 | $29.40 | 36.05% | -15.13% |
Disc Medicine Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 1 | 4 | 10 |
Avg Price Target | $89.00 | $71.00 | $60.10 |
Last Closing Price | $47.13 | $47.13 | $47.13 |
Upside/Downside | 88.84% | 50.65% | 27.52% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 23, 2024 | Jefferies | - | Buy | Initialise |
Oct 16, 2024 | Scotiabank | - | Outperform | Initialise |
Sep 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Aug 22, 2024 | Wells Fargo | - | Overweight | Initialise |
Aug 08, 2024 | Raymond James | Outperform | Outperform | Hold |
Jun 14, 2024 | Wedbush | Outperform | Outperform | Hold |
Jun 13, 2024 | BMO Capital | Outperform | Outperform | Hold |
May 10, 2024 | Raymond James | Outperform | Outperform | Hold |
Apr 02, 2024 | BMO Capital | Outperform | Outperform | Hold |
Apr 01, 2024 | Wedbush | Outperform | Outperform | Hold |
Disc Medicine Financial Forecast
Disc Medicine Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Disc Medicine EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Disc Medicine Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - |
Avg Forecast | $-33.54M | $-31.01M | $-30.97M | $-30.49M | $-32.66M | $-26.76M | $-28.33M |
High Forecast | $-33.54M | $-31.01M | $-30.97M | $-30.49M | $-32.66M | $-22.30M | $-28.33M |
Low Forecast | $-33.54M | $-31.01M | $-30.97M | $-30.49M | $-32.66M | $-30.66M | $-28.33M |
Surprise % | - | - | - | - | - | - | - |
Disc Medicine SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Disc Medicine EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - |
Avg Forecast | $-1.31 | $-1.21 | $-1.21 | $-1.19 | $-1.27 | $-1.04 | $-1.10 |
High Forecast | $-1.31 | $-1.21 | $-1.21 | $-1.19 | $-1.27 | $-0.87 | $-1.10 |
Low Forecast | $-1.31 | $-1.21 | $-1.21 | $-1.19 | $-1.27 | $-1.20 | $-1.10 |
Surprise % | - | - | - | - | - | - | - |
Disc Medicine Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
FENC | Fennec Pharmaceuticals | $4.34 | $15.75 | 262.90% | Buy |
ANEB | Anebulo Pharmaceuticals | $1.84 | $6.00 | 226.09% | Buy |
ACRV | Acrivon Therapeutics | $8.01 | $22.00 | 174.66% | Buy |
DAWN | Day One Biopharmaceuticals | $14.65 | $38.80 | 164.85% | Buy |
LRMR | Larimar Therapeutics | $7.74 | $20.33 | 162.66% | Buy |
BMEA | Biomea Fusion | $9.04 | $22.75 | 151.66% | Buy |
ABOS | Acumen Pharmaceuticals | $2.85 | $7.00 | 145.61% | Buy |
OLMA | Olema Pharmaceuticals | $11.62 | $28.50 | 145.27% | Buy |
ANAB | AnaptysBio | $21.68 | $52.33 | 141.37% | Buy |
GPCR | Structure Therapeutics | $41.14 | $92.40 | 124.60% | Buy |
MLYS | Mineralys Therapeutics | $13.45 | $30.00 | 123.05% | Buy |
TERN | Terns Pharmaceuticals | $6.94 | $14.25 | 105.33% | Buy |
MLTX | MoonLake Immunotherapeutics | $46.76 | $79.33 | 69.65% | Buy |
ADAG | Adagene | $3.00 | $5.00 | 66.67% | Buy |
IRON | Disc Medicine | $47.13 | $66.86 | 41.86% | Buy |
CNTA | Centessa Pharmaceuticals | $15.67 | $21.67 | 38.29% | Buy |
DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
CRNX | Crinetics Pharmaceuticals | $56.69 | $70.14 | 23.73% | Buy |
TRDA | Entrada Therapeutics | $17.60 | $18.00 | 2.27% | Buy |
MORF | Morphic | $56.99 | $57.00 | 0.02% | Hold |
AMLX | Amylyx Pharmaceuticals | $5.64 | $5.33 | -5.50% | Buy |
IRON Forecast FAQ
Is Disc Medicine a good buy?
Yes, according to 13 Wall Street analysts, Disc Medicine (IRON) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 92.31% of IRON's total ratings.
What is IRON's price target?
Disc Medicine (IRON) average price target is $66.86 with a range of $43 to $89, implying a 41.86% from its last price of $47.13. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Disc Medicine stock go up soon?
According to Wall Street analysts' prediction for IRON stock, the company can go up by 41.86% (from the last price of $47.13 to the average price target of $66.86), up by 88.84% based on the highest stock price target, and down by -8.76% based on the lowest stock price target.
Can Disc Medicine stock reach $70?
IRON's highest twelve months analyst stock price target of $89 supports the claim that Disc Medicine can reach $70 in the near future.
What is Disc Medicine's current price target trend?
1 Wall Street analyst forecast a $89 price target for Disc Medicine (IRON) this month, up 88.84% from its last price of $47.13. Compared to the last 3 and 12 months, the average price target increased by 50.65% and increased by 27.52%, respectively.
What are Disc Medicine's analysts' financial forecasts?
Disc Medicine's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-87.74M (high $-83.281M, low $-91.641M), average SG&A $0 (high $0, low $0), and average EPS is $-3.421 (high $-3.247, low $-3.573). IRON's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-126M (high $-126M, low $-126M), average SG&A $0 (high $0, low $0), and average EPS is $-4.913 (high $-4.913, low $-4.913).